Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	10/16/2000 7:32:08 PM
From: keokalani'nui	Read Replies (1) of 52153

Anyone have thoughts on the prospect of Enzon enjoying continued price appreciation? There is not much enzn sponsorship on SI it seems. I am concerned that the sca platform has slowed down and that Roche's branched peg-ifn is superior (recognizing that there is more than an incidental patent issue between them now) to the non-branched SGP/enzn peg-ifn. I hate having gone through a long holding period to bail on or before the date a major product come up for vote, but in these days of higher tides there seems to be less altitude to be gained after approval. All thoughts welcome. --Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next